ObjectiveTo understand the research progress of Aurora kinase A (AURKA) in colorectal cancer, so as to provide new ideas for treatment of colorectal cancer. MethodThe relevant to literature on AURKA and its relation with colorectal cancer was searched and reviewed. ResultsThe AURKA was a member of the polygenic family of mitosis/threonine protein kinases. The studies in recent years had found that the AURKA not only played an important role in the regulation in the cell cycle processes, but also played a different role outside the cell cycle. The AURKA abnormally expressed in a variety of malignancies, including colorectal cancer, and was associated with a poor prognosis in patients, and many inhibitors against AURKA were developed and evaluated at different stages of clinical study. ConclusionAs a key gene in the occurrence and development of colorectal cancer, AURKA should be further studied to clarify its specific mechanism of action, and targeted drugs may be developed.
Objective To explore the value of multi-slice spiral CT (MSCT) 3D imaging in evaluating the efficacy of neoadjuvant chemotherapy for advanced gastric cancer. MethodsSixty-one patients with gastric cancer diagnosed by gastroscopy and pathological examination at the First Hospital of Lanzhou University from January 2019 to March 2022 were divided into chemotherapy effective group (n=39) and ineffective group (n=22) according to postoperative pathological regression grade (tumor regression grade, TRG) standards. MSCT was performed before neoadjuvant chemotherapy and before undergoing surgical treatment after neoadjuvant chemotherapy. The independent predictors related to the efficacy of chemotherapy were screened by binary logistics regression analysis of CT conventional observation indexes (including maximum tumor thickness, gastric wall motility, enhancement mode, lymph node metastasis, distant metastasis, peritoneal thickening or peritoneal nodules). Tumor volume and maximum tumor thickness were measured with the imaging histology software ITK-snap, and the diagnostic efficacy of tumor volume and CT conventional observation indexes was analyzed. Results In the evaluation of chemotherapy efficacy, tumor volume reduction rate and tumor maximum thickness reduction rate can evaluate the efficacy of chemotherapy to a certain extent (P< 0.01). The statistically significant indicators (tumor maximum thickness reduction rate, gastric wall motility, lesion intensification mode and peritoneal thickening and nodules) were analyzed by univariate analysis and binary logistic regression. The results showed that gastric wall motility [OR=0.294, 95%CI (0.093, 0.928), P=0.037] and maximum tumor thickness reduction rate [OR=0.282, 95%CI (0.083, 0.957), P=0.042] were independent predictors of the efficacy of neoadjuvant chemotherapy for progressive gastric cancer. Receiver operating characteristic (ROC) curve were plotted based on the predicted probability variable obtained from both and the results showed that the area under curve (AUC=0.900) , sensitivity (83.3%), and specificity (99.8%) of the tumor volume reduction rate were all higher than those of CT clinical index prediction probability variables (AUC=0.802, sensitivity was 58.3%, specificity was 85.7%). ConclusionThe measurement of tumor volume by MSCT combined with the imaging omics software ITK-snap provides an objective basis for the prediction of the efficacy of neoadjuvant chemotherapy, and its diagnostic efficacy is better.